12 months
“We realized we could possibly cut 12 months or more from our time-to-market”
As published on celonis.com. Captured by usedby on Oct 8, 2026.
What happened
Novo Nordisk built a digital twin of its clinical trials application process in Celonis and uses Celonis Process Intelligence to power a fleet of AI agents that automate regulated clinical development workflows. It also uses the platform to diagnose whether problems lie in people, process or technology and to validate KPIs during IT modernization.
Summary written by usedby from the source page, in English. The figures are those of Celonis and Novo Nordisk, not ours.
- 100+“The team is now orchestrating a fleet of 100+ Celonis-powered AI agents”
Today, Novo Nordisk are transforming into an agentic enterprise. They’re powering a fleet of over 100 AI agents with Celonis to revolutionize clinical development. The ambition: shaving 12 months or more off drug development time to get medications into the hands of patients faster.
Without Process Intelligence, Enterprise AI at scale is hopeful thinking.
What the story claims, and what we checked
We compared the story with its live page on Oct 8, 2026.
- The figure: 12 monthsCheckedPrinted word for word on the page, near the name of Novo Nordisk.
- The passage quoted aboveCheckedCopied word for word from the page, near the name of Novo Nordisk.
- Novo Nordisk uses CelonisCheckedConfirmed line. Latest check across sources: Oct 8, 2026.
- The result itselfNot checkedWe quote it; we did not measure it.




